New drug duo targets hard-to-treat KRAS G12D cancers
NCT ID NCT07441174
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, IN10018 and RNK08954, given together to people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or metastatic cancer are being recruited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PDAC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Drum Tower Hospital, Medical School of Nanjing University
NOT_YET_RECRUITINGNanjing, Jiangsu, China
-
Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
-
Fujian Cancer Hospital
NOT_YET_RECRUITINGFuzhou, Fujian, China
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, Hunan, China
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, China
-
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
-
Shandong Cancer Hospital
NOT_YET_RECRUITINGJinan, Shandong, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital of China Medical University
NOT_YET_RECRUITINGShengyang, Liaoning, China
-
The First Affiliated Hospital of Henan University of Science and Technology
NOT_YET_RECRUITINGLuoyang, He, China
-
The First Affiliated Hospital of Wenzhou Medical University
NOT_YET_RECRUITINGWenzhou, Zhejiang, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITINGXi’an, Shanxi, China
-
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, China
-
Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310005
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI platform aims to unlock Real-World cancer data on a massive scale
- Can a genetic trait stop chemotherapy from working? a trial aims to fix that
- New drug combo aims to boost Chemotherapy's punch against pancreatic cancer
- AI could outshine standard tumor measurements to predict survival
- New drug aims to fight skin cancer in transplant patients
- New imaging agent aims to light up hidden tumors